KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Convertible Debt (2016 - 2025)

Historic Convertible Debt for Travere Therapeutics (TVTX) over the last 15 years, with Q3 2025 value amounting to $311.4 million.

  • Travere Therapeutics' Convertible Debt rose 45.59% to $311.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $311.4 million, marking a year-over-year increase of 45.59%. This contributed to the annual value of $310.3 million for FY2024, which is 1774.7% down from last year.
  • Travere Therapeutics' Convertible Debt amounted to $311.4 million in Q3 2025, which was up 45.59% from $311.0 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Convertible Debt high stood at $378.1 million for Q2 2024, and its period low was $218.1 million during Q1 2021.
  • For the 5-year period, Travere Therapeutics' Convertible Debt averaged around $326.6 million, with its median value being $374.3 million (2022).
  • Its Convertible Debt has fluctuated over the past 5 years, first surged by 7165.25% in 2022, then tumbled by 1774.78% in 2025.
  • Travere Therapeutics' Convertible Debt (Quarter) stood at $226.6 million in 2021, then soared by 65.74% to $375.5 million in 2022, then grew by 0.46% to $377.3 million in 2023, then dropped by 17.75% to $310.3 million in 2024, then increased by 0.34% to $311.4 million in 2025.
  • Its last three reported values are $311.4 million in Q3 2025, $311.0 million for Q2 2025, and $310.7 million during Q1 2025.